Targeting EZH2 methyltransferase activity has been proven to be effective in multiple neuroinflammatory diseases, such as neuropathic pain, ischemic stroke and early brain injury (EBI), revealing a cross-talk between EZH2 and TRAF6/NF-κB pathway [12, 47–49]. This evidence concerns the gene EZH2 and ischemic stroke.